The value of adding a radiation boost to postoperative radiotherapy for patients younger than 50 with early breast cancer has been confirmed by 10 years of data from the Young Boost trial conducted in the Netherlands. However, by randomizing patients between the standard radiation boost and a lower dose boost, the study demonstrated comparable efficacy for the two boost regimens, with less toxicity among patients receiving the low boost.

The trial findings were reported by Sophie Bosma, MD, PhD, Radiation Oncologist from The Netherlands Cancer Institute in Amsterdam at the 14th European Breast Cancer Conference held in Milan. After her talk, she discussed the findings with Peter Goodwin.